Revenue remained absent across all ten quarters, with R&D consuming roughly 75% to 80% of operating expenses and stock compensation of $3.1M to $4.1M per quarter partially cushioning the reported operating loss.
Design Therapeutics, Inc. (DSGN) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 834 |
| Revenue Growth % | - | - | - | - | - | - | -100% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 537K | 466K | 0 | 5K | 1.65K |
| COGS % of Revenue | - | - | - | - | - | - | - | 198.32% |
| Gross Profit | 0 | 0 | 0 | -537K | -466K | 0 | -5K | -820 |
| Gross Margin % | - | - | - | - | - | - | - | -98.32% |
| Gross Profit Growth % | - | - | 100% | -15.24% | - | 100% | -509.76% | - |
| Operating Expenses | 82.28M | 79.47M | 62.38M | 77.65M | 67.13M | 35.83M | 8.55M | 1.91M |
| OpEx % of Revenue | - | - | - | - | - | - | - | 228776.98% |
| Selling, General & Admin | 21.16M | 20.34M | 18.03M | 21.13M | 18.98M | 11.05M | 2.5M | 1.09M |
| SG&A % of Revenue | - | - | - | - | - | - | - | 130455.64% |
| Research & Development | 61.12M | 59.13M | 44.35M | 57.06M | 48.61M | 24.78M | 6.06M | 1.65M |
| R&D % of Revenue | - | - | - | - | - | - | - | 198321.34% |
| Other Operating Expenses | 0 | 0 | 0 | -537K | -466K | 0 | 0 | -834K |
| Operating Income | -82.28M | -79.47M | -62.38M | -78.19M | -67.59M | -35.83M | -8.56M | -1.91M |
| Operating Margin % | - | - | - | - | - | - | - | -228776.98% |
| Operating Income Growth % | - | -27.39% | 20.22% | -15.68% | -88.64% | -318.78% | -348.43% | - |
| EBITDA | -81.68M | -78.84M | -61.79M | -77.65M | -67.19M | -35.7M | -8.55M | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -5.56% | -27.61% | 20.43% | -15.58% | -88.19% | -317.52% | - | - |
| D&A (Non-Cash Add-back) | 600K | 622K | 596K | 537K | 406K | 129K | 5K | 1.91M |
| EBIT | -78.04M | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M | -2.05M |
| Net Interest Income | 8.2M | 9.68M | 12.79M | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 8.2M | 9.68M | 12.79M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 8.2M | 9.68M | 12.79M | 11.33M | 4.29M | 298K | 276K | -139K |
| Pretax Income | -74.09M | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M | -2.05M |
| Pretax Margin % | - | - | - | - | - | - | - | -245443.65% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -74.09M | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M | -2.05M |
| Net Margin % | - | - | - | - | - | - | - | -245443.65% |
| Net Income Growth % | -9.84% | -40.74% | 25.84% | -5.61% | -78.17% | -329.14% | -304.49% | - |
| Net Income (Continuing) | -74.09M | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M | -2.05M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.18 | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | -0.30 | -0.08 |
| EPS Growth % | -0.84% | -38.64% | 26.05% | -4.39% | -48.05% | -156.67% | -298.41% | - |
| EPS (Basic) | - | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | -0.30 | -0.08 |
| Diluted Shares Outstanding | 63.04M | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 27.19M | 27.19M |
| Basic Shares Outstanding | 63.04M | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 27.19M | 27.19M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying DSGN stock.
For fiscal year 2025, Design Therapeutics, Inc. (DSGN) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.0M in 2019.
Design Therapeutics, Inc. (DSGN) reported a net loss of $69.8M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Limited cash runway
Metrics are mathematically derived from official filings.
Pre-Revenue Profile Persists Through Ten Quarters
According to the reported income statement, DSGN has recorded no revenue across the ten quarters shown, with the only top-line activity being a $151.0K COGS entry in 2024Q2 that produced a negative gross profit, leaving growth metrics without a meaningful base.
Because revenue is absent throughout the series, year-over-year growth rates cannot be meaningfully interpreted, and the reported quarterly swings in loss per share reflect expense timing rather than commercial momentum. The lone COGS line in 2024Q2 likely relates to clinical or pre-commercial materials rather than product sales, which suggests investors should not read it as an early revenue signal. Growth durability therefore hinges entirely on future clinical milestones, not on any observable income trend.
R&D Drives Losses Despite Modest Overhead
R&D expense rose from $10.4M in 2024Q2 to $16.9M in 2026Q3, while SG&A stayed in a narrow $4.4M to $5.8M band, indicating that research spend, not overhead, is the dominant driver of the operating loss.
The operating loss widened from $15.0M to $22.2M over this period, and nearly all of that deterioration tracks R&D growth, which suggests the cost base is scaling with clinical activity rather than with administrative build-out. SG&A appears comparatively stable, implying reasonable overhead discipline. Operating leverage is effectively negative, since expenses are rising without any offsetting revenue to absorb them.
Stock Compensation Cushions Reported Cash Strain
SBC ran between $3.1M and $4.1M per quarter, roughly 15% to 20% of the reported operating loss, which means a meaningful share of the expense base is non-cash and flatters the cash burn picture.
Net loss figures are therefore somewhat overstated relative to cash consumption, and analysts should adjust for SBC when estimating runway. The 2026Q3 EPS of -0.32 beat the cited consensus of -0.39, but a single quarter's per-share figure does not establish sustainable expense control. Non-operating items appear minimal given that net loss tracks closely with operating loss.
Clinical Spend Dominates the Cost Structure
Based on the reported figures, R&D accounts for roughly 75% to 80% of total operating expenses in recent quarters, making clinical program timing the single most important determinant of quarterly burn.
Given that R&D rose by about $6.5M across the observed period while SG&A moved only marginally, expense management appears concentrated in administrative areas already held relatively flat. The cost base is largely non-discretionary while trials are active, which limits management's ability to quickly reduce burn without program delays. Investors should monitor whether upcoming trial phases push R&D materially higher.
Runway Risk Outweighs Recent EPS Improvement
The 2026Q3 loss per share of -0.32 beat consensus, but with operating losses still near $22.2M per quarter and no revenue offset, the reported figures alone suggest a financing event may be required, warranting further investigation of liquidity.
A narrower-than-expected per-share loss may reflect favorable timing of clinical spend rather than durable cost control, and the income statement does not disclose current cash or burn rates needed to confirm runway. The reported negative ROE of -30.7% and absence of revenue suggest dependence on external equity financing, which could dilute shareholders if capital is raised at depressed valuations. Analysts should treat the EPS beat cautiously until balance sheet data confirms liquidity.